Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne
Today Santhera and ReveraGen shared 2.5-year treatment data with vamorolone in Duchenne. In the announcement below the companies reported on data from 46 patients who have participated in two open-label extension studies covering 2.5 years,…Learn More